Literature DB >> 19346514

Hypervascular liver tumors: low tube voltage, high tube current multidetector CT during late hepatic arterial phase for detection--initial clinical experience.

Daniele Marin1, Rendon C Nelson, Ehsan Samei, Erik K Paulson, Lisa M Ho, Daniel T Boll, David M DeLong, Terry T Yoshizumi, Sebastian T Schindera.   

Abstract

PURPOSE: To intraindividually compare a low tube voltage (80 kVp), high tube current computed tomographic (CT) technique with a standard CT protocol (140 kVp) in terms of image quality, radiation dose, and detection of malignant hypervascular liver tumors during the late hepatic arterial phase.
MATERIALS AND METHODS: This prospective single-center HIPAA-compliant study had institutional review board approval, and written informed consent was obtained. Forty-eight patients (31 men, 17 women; age range, 35-77 years) with 60 malignant hypervascular liver tumors (mean diameter, 20.1 mm +/- 16.4 [standard deviation]) were enrolled. Pathologic proof of focal lesions was obtained with histopathologic analysis for 33 nodules and imaging follow-up after a minimum of 12 months for 27 nodules. Patients underwent dual-energy 64-section multi-detector row CT. By using vendor-specific software, two imaging protocols-140 kVp and 385 mA (protocol A) and 80 kVp and 675 mA (protocol B)-were compared during the late hepatic arterial phase of contrast enhancement. Paired t tests were used to compare tumor-to-liver contrast-to-noise ratio (CNR) for each lesion, mean image noise, and effective dose between the two data sets. Three readers qualitatively assessed the two data sets in a blinded and independent fashion. Lesion detection and characterization and reader confidence were recorded, as well as readers' subjective evaluations of image quality. Wilcoxon-Mann-Whitney statistical analysis was performed on this assessment.
RESULTS: Image noise increased from 5.7 to 11.4 HU as the tube voltage decreased from 140 to 80 kVp (P < .0001), resulting in a significantly lower image quality score (4.0 vs 3.0, respectively) with protocol B according to all readers (P < .001). At the same time, protocol B yielded significantly higher CNR (8.2 vs 6.4) and lesion conspicuity scores (4.6 vs 4.1) than protocol A, along with a lower effective dose (5.1 vs 17.5 mSv) (P < .001 for all).
CONCLUSION: By substantially increasing the tumor-to-liver CNR, a low tube voltage, high tube current CT technique improves the conspicuity of malignant hypervascular liver tumors during the late hepatic arterial phase while significantly reducing patient radiation dose.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346514     DOI: 10.1148/radiol.2513081330

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  51 in total

1.  Liver virtual non-enhanced CT with dual-source, dual-energy CT: a preliminary study.

Authors:  Long-Jiang Zhang; Jin Peng; Sheng-Yong Wu; Z Jane Wang; Xin-Sheng Wu; Chang-Sheng Zhou; Xue-Man Ji; Guang-Ming Lu
Journal:  Eur Radiol       Date:  2010-09       Impact factor: 5.315

2.  Pilot multi-reader study demonstrating potential for dose reduction in dual energy hepatic CT using non-linear blending of mixed kV image datasets.

Authors:  Anja Apel; Joel G Fletcher; Jeff L Fidler; David M Hough; Lifeng Yu; Luis S Guimaraes; Matthias E Bellemann; Cynthia H McCollough; David R Holmes; Christian D Eusemann
Journal:  Eur Radiol       Date:  2010-09-29       Impact factor: 5.315

3.  Effects of a high-pitch protocol and a hybrid iterative reconstruction algorithm on image quality of cerebral subtracted 3D CT angiography.

Authors:  Yuji Iyama; Takeshi Nakaura; Masafumi Kidoh; Naoto Kiyota; Shouzaburou Uemura; Kazunori Harada; Yasuyuki Yamashita
Journal:  Jpn J Radiol       Date:  2015-09-19       Impact factor: 2.374

4.  Evaluation of an iterative model-based reconstruction algorithm for low-tube-voltage (80 kVp) computed tomography angiography.

Authors:  Peter B Noël; Thomas Köhler; Alexander A Fingerle; Kevin M Brown; Stanislav Zabic; Daniela Münzel; Bernhard Haller; Thomas Baum; Martin Henninger; Reinhard Meier; Ernst J Rummeny; Martin Dobritz
Journal:  J Med Imaging (Bellingham)       Date:  2014-10-09

5.  Spectral CT in patients with small HCC: investigation of image quality and diagnostic accuracy.

Authors:  Peijie Lv; Xiao Zhu Lin; Kemin Chen; Jianbo Gao
Journal:  Eur Radiol       Date:  2012-05-23       Impact factor: 5.315

6.  Combining automated attenuation-based tube voltage selection and iterative reconstruction: a liver phantom study.

Authors:  Daniela B Husarik; Sebastian T Schindera; Fabian Morsbach; Natalie Chuck; Burkhardt Seifert; Zsolt Szucs-Farkas; Hatem Alkadhi
Journal:  Eur Radiol       Date:  2013-10-24       Impact factor: 5.315

Review 7.  Computed tomography--old ideas and new technology.

Authors:  Dominik Fleischmann; F Edward Boas
Journal:  Eur Radiol       Date:  2011-01-20       Impact factor: 5.315

8.  Image quality and radiation dose of dual-energy CT of the head and neck compared with a standard 120-kVp acquisition.

Authors:  A M Tawfik; J M Kerl; A A Razek; R W Bauer; N E Nour-Eldin; T J Vogl; M G Mack
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-08       Impact factor: 3.825

9.  Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques.

Authors:  Fabian Morsbach; Bert-Ram Sah; Lea Spring; Gilbert Puippe; Sonja Gordic; Burkhardt Seifert; Niklaus Schaefer; Thomas Pfammatter; Hatem Alkadhi; Caecilia S Reiner
Journal:  Eur Radiol       Date:  2014-05-12       Impact factor: 5.315

10.  Model-based iterative reconstruction versus adaptive statistical iterative reconstruction and filtered back projection in liver 64-MDCT: focal lesion detection, lesion conspicuity, and image noise.

Authors:  William P Shuman; Doug E Green; Janet M Busey; Orpheus Kolokythas; Lee M Mitsumori; Kent M Koprowicz; Jean-Baptiste Thibault; Jiang Hsieh; Adam M Alessio; Eunice Choi; Paul E Kinahan
Journal:  AJR Am J Roentgenol       Date:  2013-05       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.